Page last updated: 2024-08-21

treosulfan and Agnogenic Myeloid Metaplasia

treosulfan has been researched along with Agnogenic Myeloid Metaplasia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Assanelli, A; Bernardi, M; Carrabba, M; Ciceri, F; Claudiani, S; Corti, C; De Freitas, T; Giglio, F; Guggiari, E; Lunghi, F; Lupo-Stanghellini, MT; Marcatti, M; Marktel, S; Peccatori, J; Piemontese, S1
Buss, EC; Fruehauf, S; Ho, AD; Kreipe, HH; Topaly, J1
Buss, EC; Fruehauf, S; Ho, AD; Kreipe, HH; Tropaly, J1

Other Studies

3 other study(ies) available for treosulfan and Agnogenic Myeloid Metaplasia

ArticleYear
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.
    Hematological oncology, 2016, Volume: 34, Issue:3

    Topics: Aged; Allografts; Busulfan; Disease-Free Survival; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine

2016
Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses - follow-up of three patients.
    Haematologica, 2005, Volume: 90, Issue:2

    Topics: Antigens, CD34; Busulfan; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Primary Myelofibrosis; Transplantation Conditioning; Treatment Outcome

2005
Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses. A follow-up of three patients.
    Haematologica, 2005, Volume: 90, Issue:1

    Topics: Antigens, CD34; Antineoplastic Agents, Alkylating; Busulfan; Female; Follow-Up Studies; Humans; Peripheral Blood Stem Cell Transplantation; Primary Myelofibrosis; Transplantation Conditioning; Transplantation, Autologous

2005